Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Receivables - Net for 5 consecutive years, with $1.1 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 3021.14% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 3021.14% year-over-year, with the annual reading at $11948.0 for FY2025, N/A changed from the prior year.
- Receivables - Net for Q4 2025 was $1.1 million at Neuphoria Therapeutics, up from $1758.0 in the prior quarter.
- The five-year high for Receivables - Net was $4.9 million in Q2 2022, with the low at $1758.0 in Q3 2025.
- Average Receivables - Net over 4 years is $771101.8, with a median of $30076.5 recorded in 2024.
- The sharpest move saw Receivables - Net plummeted 99.8% in 2023, then soared 3021.14% in 2025.
- Over 4 years, Receivables - Net stood at $4.9 million in 2022, then tumbled by 99.8% to $9836.9 in 2023, then skyrocketed by 261.51% to $35561.0 in 2024, then skyrocketed by 3021.14% to $1.1 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $1.1 million, $1758.0, and $11948.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.